<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="abstract"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Eur Psychiatry</journal-id><journal-id journal-id-type="publisher-id">EPA</journal-id><journal-title-group><journal-title>European Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">0924-9338</issn><issn pub-type="epub">1778-3585</issn><publisher><publisher-name>Cambridge University Press</publisher-name><publisher-loc>Cambridge, UK</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11862465</article-id><article-id pub-id-type="doi">10.1192/j.eurpsy.2024.1580</article-id><article-id pub-id-type="other">EPV0993</article-id><article-id pub-id-type="pii">S0924933824015803</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstract</subject></subj-group><subj-group subj-group-type="section"><subject>e-Poster Viewing</subject></subj-group></article-categories><title-group><article-title>Relationship between circadian rhythm and Malondialdehyde serum levels in acute and stabilized schizophrenic patients</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>D&#x000ed;az-Mesa</surname><given-names>E.</given-names></name><xref rid="aff3427" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff3428" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>C&#x000e1;rdenes Moreno</surname><given-names>C.</given-names></name><xref rid="aff3427" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Morera-Fumero</surname><given-names>A.</given-names></name><xref rid="aff3428" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Perez-Sagaseta De Ilurdoz</surname><given-names>I.</given-names></name><xref rid="aff3427" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cor1429" ref-type="corresp">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Abreu-Gonz&#x000e1;lez</surname><given-names>P.</given-names></name><xref rid="aff3429" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Cejas-M&#x000e9;ndez</surname><given-names>M. R.</given-names></name><xref rid="aff3427" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff3428" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Fern&#x000e1;ndez-L&#x000f3;pez</surname><given-names>M. L.</given-names></name><xref rid="aff3428" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Henry-Ben&#x000ed;tez</surname><given-names>M. S.</given-names></name><xref rid="aff3428" ref-type="aff">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="aff3427"><sup>1</sup>PSIQUIATR&#x000cd;A, <institution>HOSPITAL UNIVERSITARIO DE CANARIAS</institution></aff><aff id="aff3428">
<sup>2</sup>
<institution>MEDICINA INTERNA, PSIQUIATR&#x000cd;A Y DERMATOLOG&#x000cd;A</institution>
</aff><aff id="aff3429"><sup>3</sup>FISIOLOG&#x000cd;A, <institution>UNIVERSIDAD DE LA LAGUNA, SAN CRISTOBAL DE LA LAGUNA</institution>, <country>Spain</country></aff><author-notes><corresp id="cor1429"><label>*</label>Corresponding author.</corresp></author-notes><pub-date publication-format="electronic" date-type="collection" iso-8601-date="2024-04"><month>4</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>27</day><month>8</month><year>2024</year></pub-date><volume>67</volume><issue seq="1555">Suppl 1</issue><issue-title content-type="special_issue">Abstracts of the 32nd European Congress of Psychiatry</issue-title><fpage>S759</fpage><lpage>S759</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<uri xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</uri>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="S0924933824015803a.pdf"/><abstract><sec id="sec8590"><title>Introduction</title><p>Malondialdehyde (MDA) is a product of polyunsaturated fatty acid peroxidation (Del Rio D, et al. A review of recent studies on MDA as toxic molecule and biological marker of oxidative stress. Nutr Metab Cardiovasc Dis. 2005;15:316-28). It is a biomarker of oxidative stress and is involved in the pathophysiology of schizophrenia (Goh et al. Asian J Psychiatr. 2022;67:102932). Schizofrenia is linked to disrupted oxidative balance and inflammation (Wi&#x00119;d&#x00142;ocha et al. Brain Sci. 2023;13:490). Prior research has shown connections between biomarkers and circadian rhythms in schizophrenia (Morera &#x00026; Abreu. Acta Physiol Scand. 2007;43:313-14) and diabetes type 2 (Kanabrocki EL, et al. Circadian variation in oxidative stress biomarkers in healthy and type II diabetic men. Chronobiol Int. 2002;19:423-39). To determinate if MDA levels have a role in schizophrenia and follow a circadian rhythm may be useful.</p></sec><sec id="sec8591"><title>Objectives</title><p>The aim of our study is to compare diurnal and nocturnal MDA serum levels in patients in acute and stabilized phases of schizophrenia according to CIE-10 to find out if there are variations related with circadian rhythms</p></sec><sec id="sec8592"><title>Methods</title><p>47 patients were included in our study in two clinical phases: acute episode and stabilization. Blood samples were collected at 12:00h and at 00:00h. MDA serum levels were measured twice: when patients were decompensated (admission) and at clinical stabilization (discharge). The relationship between quantitative variables at both times was analysed by T-Student test</p></sec><sec id="sec8593"><title>Results</title><p>There is no significative difference between night and day MDA levels in the acute phase of the schizophrenia (2.22&#x000b1;1.352 vs. 1.93&#x000b1;1.530, p&#x0003c;0.09). There is statistical significance between 12:00 and 00:00 (1.90&#x000b1;1.136 vs. 1.34&#x000b1;0.868, p&#x0003c;0.001) at discharge: it was observed that levels decreased. This result can be interpreted as there is circadian rhythm in stabilized phases.</p></sec><sec id="sec8594"><title>Conclusions</title><p>
MDA levels in patients with schizophrenia do not follow a circadian rhythm in the acute episode. When they are clinically stabilized present a circadian change. These patients lose the circadian rhythm in acute episodes. MDA circadian rhythm may help diagnose the clinical phase and its severity. It is necessary to perform more studies to know its utility as an oxidative biomarker</p></sec><sec id="sec8595"><title>Disclosure of Interest</title><p>None Declared</p></sec></abstract><counts><page-count count="1"/></counts></article-meta></front></article>